Use of liquid chromatography tandem mass spectrometry for the quantitative and qualitative analysis of an antipsychotic agent and its metabolites in human plasma and urine

被引:25
作者
Dear, GJ
Fraser, IJ
Patel, DK
Long, J
Pleasance, S
机构
[1] GlaxoWellcome, Grp Dev Operat, BioMet Div, Beckenham BR3 3BS, Kent, England
[2] GlaxoWellcome, Grp Dev Operat, BioMet Div, Res Triangle Pk, NC 27709 USA
关键词
tandem mass spectrometry; 2-amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl) benzamide; antipsychotic agent;
D O I
10.1016/S0021-9673(97)00688-2
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The use of liquid chromatography-tandem mass spectrometry (LC-MS-MS) for the quantitative analysis of an 'atypical' antipsychotic agent in human plasma is described. The method uses atmospheric pressure chemical ionisation, and offers increased sensitivity, selectivity and speed of analysis over an existing high-performance liquid chromatography method using fluorescence detection. This method enabled same day turn around of results for in excess of 100 samples, including sample preparation, data acquisition and processing. LC-MS-MS was also used to detect and characterise known and unknown in vivo metabolites of the drug in human urine and plasma, using electrospray ionisation. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:27 / 36
页数:10
相关论文
共 14 条
[1]   POSITIVE VS NEGATIVE SCHIZOPHRENIA - A CRITICAL-EVALUATION [J].
ANDREASEN, NC .
SCHIZOPHRENIA BULLETIN, 1985, 11 (03) :380-389
[2]   SEROTONIN, SCHIZOPHRENIA AND ANTIPSYCHOTIC DRUG-ACTION [J].
BREIER, A .
SCHIZOPHRENIA RESEARCH, 1995, 14 (03) :187-202
[3]   THE CURRENT STATUS OF THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA [J].
CARLSSON, A .
NEUROPSYCHOPHARMACOLOGY, 1988, 1 (03) :179-186
[4]   IDENTIFICATION OF URINARY AND BILIARY CONJUGATED METABOLITES OF THE NEUROMUSCULAR BLOCKER 51W89 BY LIQUID-CHROMATOGRAPHY MASS-SPECTROMETRY [J].
DEAR, GJ ;
HARRELSON, JC ;
JONES, AE ;
JOHNSON, TE ;
PLEASANCE, S .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 1995, 9 (14) :1457-1464
[5]  
FLEISCHHACKER WW, 1995, ACTA PSYCHIAT SCAND, V91, P24
[6]   THE EVOLUTION OF THE SEROTONIN-DOPAMINE ANTAGONIST CONCEPT [J].
HUTTUNEN, M .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1995, 15 (01) :S4-S10
[7]  
JANN MW, 1991, PHARMACOTHERAPY, V11, P179
[8]   Preclinical neurochemical and electrophysiological profile of 1192U90, a potential antipsychotic [J].
JonesHumble, SA ;
Durcan, MJ ;
Lyerly, D ;
Norton, RM ;
Tang, FLM ;
Russell, AV ;
Watson, MJ ;
Gengo, PJ ;
Morgan, PF ;
Wang, CM ;
Cooper, BR ;
Cox, RF .
NEUROPSYCHOPHARMACOLOGY, 1996, 15 (03) :217-230
[9]  
KOREEN AR, 1993, AM J PSYCHIAT, V150, P1643
[10]  
LIBERMAN RP, 1992, J NEUROPSYCH CLIN N, V4, P119